Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML.

Imatinib resistance is an important hurdle in the treatment of chronic myeloid leukemia (CML), and CML patients with this drug resistance are often given a dismal prognosis. In this case report, an im